On Wednesday, Upstream Bio got an upgrade to its Relative Strength (RS) Rating, from 73 to 82.
This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a consolidation and break out.
The company posted 0% earnings growth in its most recent report, while sales growth came in at -11%.
Upstream Bio holds the No. 242 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Harmony Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
